Allergic Rhinitis News and Research

RSS

Extract of French maritime pine tree bark reduces hay fever symptoms

An estimated 60 million people in the U.S. are affected by allergic rhinitis, commonly known as hay fever, according to the American Academy of Allergy Asthma and Immunology. Hay fever is an allergic inflammation of the nasal airways that causes itching, swelling, mucus production, hives and rashes. A study published in the June 14, 2010 issue of Phytotherapy Research demonstrates Pycnogenol- (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, substantially improves the symptoms of hay fever.

24 Jun 2010

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from clinical and preclinical studies demonstrating the ability of tranilast to reduce serum uric acid levels and monosodium urate crystal-induced inflammation - two important risk factors for gout - were presented at The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.

22 Jun 2010

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites.

21 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.

5 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

Prevalence of scalp fungus infection among children living in metropolitan areas

Approximately 7 percent of elementary school children across the bi-state, Kansas City metropolitan area are infected with the fungus Trichophyton tonsurans (T. tonsurans), the leading cause of ringworm in the U.S., according to a new study published today in Pediatrics. This is the largest study to date aimed at defining infection prevalence of the scalp fungus in children living in a metropolitan area and has implications for children nationwide.

20 Apr 2010

7% of elementary school children infected with T. tonsurans: Pediatrics

Approximately 7 percent of elementary school children across the bi-state, Kansas City metropolitan area are infected with the fungus Trichophyton tonsurans, the leading cause of ringworm in the U.S., according to a new study published today in Pediatrics.

19 Apr 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

16 Mar 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

Eczema in early childhood may influence behavior and mental health later in life

Eczema in early childhood may influence behavior and mental health later in life. This is a key finding of a prospective birth cohort study to which scientists of Helmholtz Zentrum München contributed.

11 Feb 2010

Eczema can lead to behavioral and psychological problems in children

11 Feb 2010

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

A joint GA²LEN /EAACI report to be published in "Allergy" and available online on 8 February reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA²LEN, an EU-funded Network of Excellence.

10 Feb 2010

Researchers to study the impact of asthma on sleep and academic performance of young children

Bradley Hasbro Children's Research Center and Hasbro Children's Hospital researchers have received more than $2.5 million in direct costs from The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to study the impact of asthma on the sleep quality and academic performance of young children.

22 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

Allergic Rhinitis News and Research

Extract of French maritime pine tree bark reduces hay fever symptoms

Nuon study confirms potential utility of tranilast as uricosuric agent

Staloral 300 demonstrates efficacy in phase III study for control of asthma in China

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Prevalence of scalp fungus infection among children living in metropolitan areas

7% of elementary school children infected with T. tonsurans: Pediatrics

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Merck announces global sales of $27.4 billion for full-year 2009

Meda publishes 2009 year-end report

Alcon reports 2009 fourth quarter results

Eczema in early childhood may influence behavior and mental health later in life

Eczema can lead to behavioral and psychological problems in children

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

Researchers to study the impact of asthma on sleep and academic performance of young children

VentiRx Pharmaceuticals completes $25 million Series A Extension

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News